RecruitingPeripheral Arterial Disease
Effects of Carnosine In Patients With Peripheral Arterial Disease Patients
Eligible age
40–80 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to determine whether carnosine (a food ingredient found in chicken and red meat) supplementation (2 g) for 6 months in participants with non-claudication and claudication peripheral arterial disease (PAD) improves walking ability. Previous studies with heart failure patients have shown that carnosine supplementation increases walking capacity in these patients.
Sponsor: Shahid Baba
You may qualify if…
- ✓ 1. Participants between 40-80 years of age.
- ✓ 2. White or African American race.
- ✓ 3. Literate in English.
- ✓ 4. ABI \>0.4-\<0.90, obtained within 6 weeks from enrollment.
- ✓ 5. Willing and able to comply with protocol requirements.
- ✓ 6. Participant is able to provide informed consent.
You may not qualify if…
- ✕ 1. As per physician's discretion, participants with HIV, hepatitis, significant liver disease, anemia, renal disease requiring dialysis, lung disease requiring home oxygen therapy, and active cancer may be excluded.
- ✕ 2. Critical limb ischemia with below or above the knee amputations or any form of foot ulceration over the symptomatic leg.
- ✕ 3. Presence of significant injury within 30 days, or vascular intervention on the symptomatic leg within 6 months before enrollment, as per physician's discretion.
- ✕ 4. Participants with a baseline 6MWT of less than 152.0 meters (498ft) or greater than 487.7 meters (1600ft).
- ✕ 5. Known allergy to L-carnosine.
- ✕ 6. Participants with rare autosomal recessive metabolic disorder carnosinemia or carnosinase deficiency.
- ✕ 7. Currently participating in other clinical trials.
- ✕ 8. Participation in any carnosine supplementation clinical trial anytime in the past.
Where it's recruiting
Kentucky
Louisville
Source: ClinicalTrials.gov · NCT06480760 · last updated 2025-05-29